Dr Jeanette Wood has joined Nuevolution’s board of directors and will also serve as scientific advisor to the board.
The Danish small molecule drug discovery company also welcomes Henrik Simonsen as Chief Financial Officer.
Wood has extensive experience in all aspects of drug discovery from target validation, lead optimisation, biomarker development, through to translational research in support of clinical trials as well as experience in multiple therapeutic areas.
She is presently CSO at Switzerland-based biotech company Genkyotex.
Born and educated in New Zealand, Wood began her drug discovery career in the cardiovascular area at Ciba-Geigy in Switzerland. Early research was focused on innovative small molecule drugs targeting the renin-angiotensin system and later, in Novartis, on anti-angiogenesis therapies for cancer and inflammatory diseases. Wood left Novartis to join Singapore-based S*BIO, as Head of Biology.
Before joining Genkyotex, Wood held senior management positions at AstraZeneca, where she was responsible for the early discovery portfolio within oncology including biology, chemistry and DMPK functions.
Nuevolution has also appointed Henrik Simonsen as Chief Financial Officer. As a member of the company’s Executive Management team, he will play a key part in strategy planning going forward. His most recent position was at SEB, where he was responsible for the life science arm of the corporate finance practice.
Simonsen has more than 20 years of experience as an equity analyst covering Nordic, European and US life science companies as well as a number of years of corporate finance experience.
